Target intelligence / Profile preview

Agkistrodon acutus venom metalloproteinase (AaVMP)

Target
AaVMP
Molecular classification
Enzyme, Metallopeptidase, Reprolysin family, M12B family
01

Overview

Agkistrodon acutus venom metalloproteinases (SVMPs) are a diverse group of zinc-dependent proteolytic enzymes found in the venom of the sharp-nosed pit viper, a medically significant snake species in East Asia (UniProt Consortium, 2024). These enzymes, which include specific isoforms like acutolysin A, B, and C, belong to the reprolysin (M12B) family and are the primary agents responsible for the severe local and systemic hemorrhage characteristic of A. acutus envenomation (Bi et al., 2005). SVMPs function by degrading key structural components of the vascular basement membrane, such as type IV collagen, laminin, and fibronectin, which leads to the weakening and eventual rupture of capillary vessels (Sánchez and Rodríguez-Acosta, 2008). Beyond their hemorrhagic activity, these enzymes also contribute to tissue necrosis and interfere with the coagulation cascade by degrading fibrinogen or activating prothrombin (Toxins, 2018). The primary therapeutic intervention is the administration of specific antivenoms, which contain antibodies that bind and neutralize the toxins (World Health Organization, 2016). Additionally, research into small-molecule inhibitors like batimastat and marimastat suggests potential for adjunctive therapy to limit early tissue damage before hospital-based antivenom treatment is available (PubMed, 2021).

Other names
AcutolysinSharp-nosed pit viper venom metalloproteinaseHundred-pace viper venom metalloproteinaseSnake venom metalloproteinaseSVMP
02

Mechanism of action

Neutralization of proteolytic activity through antibody binding or competitive inhibition of the zinc-dependent catalytic site.

03

Biological functions

ProteolysisExtracellular matrix degradationHemorrhage inductionFibrinogenolysisPlatelet aggregation inhibition
04

Disease associations

Snakebite envenomationHemorrhageTissue necrosisCoagulopathy
05

Safety considerations

Antivenom-induced anaphylaxisSerum sicknessOff-target inhibition of human matrix metalloproteinasesRapid onset of irreversible tissue necrosis
06

Interacting drugs

Agkistrodon acutus antivenom

5 more in the full profile.

07

Biomarkers

Fibrinogen levelProthrombin time (PT)Activated partial thromboplastin time (aPTT)D-dimerCreatine kinase

Beyond the preview

Go deeper on Agkistrodon acutus venom metalloproteinase (AaVMP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agkistrodon acutus venom metalloproteinase (AaVMP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call